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The International Committee of Medical Journal Editors (ICMJE) provides recommendations to improve the editorial standards and 
scientific quality of biomedical journals. These recommendations range from uniform technical requirements to more complex and 
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disclosure, and new criteria for authorship -emphasizing the importance of responsibility and accountability-, have been proposed. This 
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The Editors´  Network of the European Society of Cardiology 
(ESC) is committed to promote the implementation of high-quality 
editorial standards among ESC National Societies Cardiovascular 
Journals (NSCJ).1-4) NSCJ play a major role in disseminating high-
quality scientific research. However, they also play a relevant role 
in education and harmonization of clinical practice.3) Most NSCJ 
are published in local languages but many have English editions 
and have gained international scientific recognition.1-4) NSCJ nicely 
complement ESC official journals and, altogether, provide an 
effective means to disseminate European cardiovascular research. 
In a globalized and highly competitive editorial environment, 
promoting high quality editorial standards remain of paramount 
importance to increase the scientific prestige of NSCJ.1-4) From 
its conception the Editors´  Network strongly advocated for the 
adherence to the uniform recommendations of the International 
Committee of Medical Journal Editors (ICMJE).1) In the mission 
statement document the Editors´  Network committed to adapt 
NSCJ to follow these general editorial recommendations.1) However, 
NSCJ are highly heterogeneous in scope and contents and 
these new recommendations should be embraced progressively, 
considering currently existing editorial policies and the editorial 
freedom of the NSCJ.1-4)
Ethical issues play a growing role in ensuring the credibility 
of the scientific process.5-13) Biomedical research relies on trust. 
However, transparency also represents a major tenet in the 
scientific process.5-8) This review will discuss the new editorial 
recommendations on data sharing issued by the ICMJE.14) Novel 
ICMJE recommendations always appear as provocative, and 
often as too ambitious, when initially presented. Moreover, 
implementation of editorial changes is rather demanding from a 
technical and logistic point of view. Adherence to novel editorial 
initiatives is challenging not only for editors but also for the entire 
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scientific community. Therefore, many Editors have a natural 
tendency to avoid stepping ahead as early adopters of new 
“editorial experiments” and usually prefer keep moving in their 
comfort zone until the “sea change” has matured.1-4) However, 
experience has thought us that all editorial initiatives developed 
by the ICMJE eventually prevail playing a critical role to maintain 
the credibility of the scientific process.9-13) Highly successful recent 
examples include trial registration, conflicts of interest initiative 
and the new requirements for authorship.9-13)
The novel ICMJE recommendations on data sharing14) are 
discussed herein from a didactic perspective with the aim to 
provide new editorial insights and hopefully to be progressively 
adopted and implemented by the NSCJ. 
Sharing Clinical Trial Data: The New ICMJE Proposal
The ICMJE considers that there is a moral obligation to responsible 
share the data generated by clinical trials.14) The rationale 
underlying this global endeavor is that patients have assumed a 
risk by accepting to participate in a trial. Accordingly, making the 
obtained data publicly available represents a responsible initiative 
to facilitate the advancement of science. Sharing the data would 
increase trust in the conclusions reach by trials. Indeed, data sharing 
allows confirmation of the results by independent researches.14) 
Furthermore, new hypothesis may be pursuit by different groups of 
investigators. This initiative may foster leveraging data to answer 
different research questions or scientific inquiries not contemplated 
in the original study. If science becomes an open process many 
researchers would benefit of taking advantage of reliable data 
generated somewhere else. Therefore, data sharing emerges as the 
best way to ensure that all the information gathered by trials is 
made freely and widely available, so that it can be readily used to 
advance scientific knowledge.14) The use of previously collected data 
to further advance science is difficult to be criticized. As discussed, 
this honours the volunteerism of the patients who signed up and 
consented to participate in a trial. 
Governments, funding agencies, scientific societies, the industry 
and even the lay society growingly demand sharing clinical trial 
data. Therefore, the ICMJE suggests that editors should help 
to meet this ethical obligation by devising new editorial policies 
specifically addressing this issue.14) 
The first consideration is to clarify what is exactly a clinical trial. 
According to the ICMJE definition, a clinical trial is a study that 
prospectively assigns people to an intervention in order to assess 
the cause-and-effect relationship between that intervention and 
the ensuing health outcome.5)
The ICMJE considers that sharing “de-identified” individual 
patient data should become part of the publication process of 
clinical trials.14) This strategy protects patient´s confidentiality 
rights. The requirement, however, is restricted to the individual-
patient data underpinning the results presented in the published 
article. Importantly, a clear plan for data sharing should be disclosed 
at the time of initial trial registration and should be also presented 
at the time of manuscript submission. The proposal requires clinical 
trialists to declare that they will share their data publically as a 
prerequisite for publishing the trial.14) They should compromise to 
freely release individual patient raw data at the time they submit 
the manuscript for consideration. 
It is important to keep in mind that clinical trial registration was 
a previous ICMJE editorial initiative aimed to address problems 
related to publication bias (selective publication of positive trials), 
endpoints inconsistency and redundant research.9)10) Potentially, 
public repositories provide an optimal means not only for initial 
trial registration but also for individual-patient data sharing. From 
now on the plan for data-sharing would be an important step of 
the clinical trial registration initiative.9)10)14) Details on whether the 
data would be freely available upon request, or only after a formal 
application, that eventually will be approved after an agreement 
is reached on data use conditions, should be presented. Finally, 
it has been proposed that the data should be made public no 
more than 6 months after publication of the original study in 
the journal.9)10)14) Clinicaltrials.com, a widely used non-for profit 
scientific repository,9)10) has already adapted its registration 
platform to specifically clarify data-sharing plans at the time of 
clinical trial registration.
Proponents of “open science” will be pleased by this new 
requirement for sharing clinical trial data.14) Obviously, this editorial 
initiative may have profound consequences on the planning, 
conduction and reporting of clinical trials and, in fact, may deeply 
influence research and publication strategies.14) As a result, the idea 
is to implement this requirement for any clinical trial that begins 
to enroll patients 1 year after the official adoption of this editorial 
policy by the corresponding journal.14) The initiative will also have 
major implications for the editorial process. Indeed, Editors are 
supposed to monitor the data sharing process and, eventually, 
address potential irregularities. These might include requests of 
clarification to the authors, notification to academic institutions, 
publication of expressions or concern or even retractions. 
Finally, the ICJME acknowledges that the rights of the 
investigators and sponsors should be protected.14) Moreover, credit 
to the original report should be granted by including a unique 
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identifier of the data set. It is emphasized that credit should be 
always given to the original investigators that posted the data after 
publication of their research. Furthermore, additional investigators 
using these databases should request collaboration of the original 
investigators that originally collected the data to ensure adequate 
data interpretation, management and analysis. 
Pending Issues on Data Sharing
Although it appears clear that this initiative will further 
improve transparency and the overall integrity of the scientific 
literature, some remaining issues need to be addressed. There 
are inherent resistance to embrace open science initiatives from 
some academic institutions or investigators that defend the idea 
of exploiting their “own” data.15)16) Until now clinical researchers 
were discouraged from working with clinical trial data they did 
not generate themselves.15)16) Likewise, trialists tended to see trial 
data as their personal property and would routinely refuse requests 
for data sharing. In fact, until recently most researchers and 
pharmaceutical industry groups were opposed to making raw data 
available after trial publication. This practice, however, differs from 
other disciplines (as genomics or economics) where data sharing is 
common place.15)16) 
Obtaining reliable, high-quality original data requires a major 
research effort. A sufficient period of time from the time of article 
publication to the need to share the raw data should be allowed to 
give original investigators the possibility of publishing additional 
subgroup analyses from their own data.14) This new proposal 
will further increase the pressure on academic investigators 
that frequently have not the required resources to publish their 
subsequent analyses and require time to prepare the new the 
manuscripts.14) Notably, most researchers have no experience with 
the process of releasing or dealing with public data. Furthermore, 
the effort and resources required to organize the raw data in a 
way that would be comprehensible to others investigators remain a 
cause of major concern.14) 
Data-access to non-trial researches may disclose problems not 
recognized by the initial investigators. Although this will increase 
transparency and, therefore, trust in trial results, it might also 
generate confusion and undue scientific controversies. It is difficult 
to envision how the new researches will gain the required detailed 
knowledge of the complicated datasets enjoyed by the original trial 
investigators.14) A reliable assessment of the data requires a deep 
knowledge on the study background and to be able to properly 
address many nuances and practical considerations. These include 
precise information on the way variables were defined, how data 
was collected and how results were finally coded and entered into 
the database. The initiative might be fraught with problems related 
to incorrect analysis resulting in inaccurate results and erroneous 
interpretations, potentially damaging science.14) 
Finally, Editors, already deluged with work, will need to check 
that all of the raw data of the published articles has been 
eventually released as promised. Different results may emerge 
from misconceptions regarding what data should be analysed to 
answer specific questions.14) If there are differences in results, it will 
be difficult to decide which analysis provides the most accurate 
reflection of the data. This could generate an undue “scientific 
noise”, with contradictory results and rectifications, which may 
generate confusion and frustration in the scientific community. 
Finally, this may also promote the simultaneous publication in 
several journals of conflicting results from the same database by 
different groups.14) 
As many issues should be still clarified the ICMJE asked for 
feedback on its preliminary editorial proposal on clinical trial data 
sharing before April 18, 2016.14) Obviously, the initiative will only 
gain the required maturity from the experience gained during its 
adoption and implementation. 
Previous Initiatives on Data Sharing
Several leading academic entities have been previously working 
on this field. The British Medical Journal pioneered an editorial 
initiative of data sharing.17) In 2012 this policy took effect only for 
trials on drug and devices but, in 2015, the requirement of data 
sharing “on request” was extended to all submitted clinical trials.17) 
Some have proposed that individual patient data may also be 
of major value during the “peer review” process by permitting 
independent verification of the results before final publication.18) 
Although this initiative might be of potential value most reviewers 
are already deluged with work and this extra task could generate 
fatigue and burn out phenomena. In addition, many good clinical 
reviewers do not have the expertise required to manage data and 
to perform confirmatory statistical analyses.18) Some journals, as 
JAMA, previously developed some related initiatives including 
the request for independent statistical analyses by an academic 
statistician of industry-sponsored trials.19) 
The World Health Organization (WHO) and the Institute of 
Medicine (IOM) also announced important declarations on clinical 
trial transparency. The IOM issued specific guidelines for trial data 
sharing.20) WHO initially presented a statement on public disclosure 
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of clinical trial results and, subsequently, encouraged sharing 
of research datasets whenever appropriate.21-23) More recently, 
the WHO developed global norms for sharing data and results 
during public health emergencies, with special focus on clinical, 
epidemiologic, and genetic features of new infectious diseases and 
experimental therapeutics and vaccines. In emergency situations, 
data need to be shared quickly before the information is published.23) 
The National Health, Lung and Blood Institute (NHLBI) also 
developed detailed data-sharing practices allowing public access 
to trial raw data and a data repository currently including over half 
a million patients from over 100 trials and observational studies.24) 
In 2015 the NHLBI discussed its intent to make public digital data 
from its funded trials.24)
Platforms and Repositories
Up to 30000 clinical trials are conducted annually worldwide 
generating a huge volume of patient-level raw data.25) Currently, 
however, available portals for data sharing are still not adequate. 
Most of them require a time consuming request, including a 
detailed research proposal with the study design, main endpoints 
and a statistical plan.25) The submitted proposal is then reviewed 
by an independent research panel that decides whether to approve 
the request for data.25) Currently, this process takes too long. When 
eventually the data is obtained oftentimes it is not readily usable. 
For instance, variable names may be not informative and long 
annotation files need to be carefully revised.25)
The requirement of elaborating a detailed research proposal 
to request data access ensure an adequate review process.21)26) 
However, the means to facilitate data sharing from the data 
holder to the researcher may be cumbersome and challenging to 
implement. Some systems provide an electronic form or template.21) 
However, when these are not available a de novo proposal should 
be generated outlining the purpose, the statistical analysis plan, the 
research team, and potential conflicts of interest. The review process 
may come from an internal or external review panel selected by 
the data holder or by a third party.25-27) Finally, data can be shared 
through a public website or by direct communication between the 
data holder and the researcher. In most cases, however, controlled 
access is required. Before any analysis is started reviewing all 
the accompanying documentation to assist the researcher in the 
understanding of the original clinical trial and the methodology 
used, remains critical. Furthermore, the data holder may require a 
legally binding data sharing agreement and should be available to 
provide the required support when questions arise.27)
Major care should be taken to prevent the perils that may 
undermine the value of data sharing.14) Data from trials should 
be responsibly used.28) A recent survey from UK Clinical Trial Units 
disclosed some potential risks associated with data sharing.29) 
These basically included misused of data, incorrect secondary 
analyses, resource requirements and identification of patients.29)30) 
Researches are responsible to present the data in a format 
amenable for external secondary use. Repositories should be 
prepared to make raw data available in standardized platforms in 
a fully comprehensive manner. It is clear that funding is required 
to help the researches in these tasks. Data sharing from trials 
with anonymized patient-level data with associated metadata 
and supporting information should be made available to other 
researchers following an independent analysis of the research 
proposals. Developing and adopting a standard approach to 
protecting patient privacy is urgently required.14) 
Some academic research organization consortiums focussed on 
the study of cardiovascular diseases,31) have developed interesting 
tools for data sharing. Presentation of a standardized request in a 
Web portal is required. Proposals are to be analyzed by a scientific 
committee, including members designed by the consortium and a 
statistician along with the trial’s principal investigator. The idea is 
to ensure an adequate use of the data base and correct statistical 
analyses while averting the problem of multiple investigators 
proposing the same analyses.31) 
Finally, an adequate infrastructure should be organized to support 
effective data sharing. In this regard, the role of the industry is 
significantly growing as demonstrated by some joint initiatives, as 
the Yale University Open Data (YODA) project.16)32)
Statistical Issues
Statisticians play a key role in developing data sharing strategies.33) 
They should be involved from the very beginning to organize the 
research strategy and the required analytical techniques.33) A data 
sharing working group of medical research statisticians, from 
the pharmaceutical and biotechnological industry and from the 
academia, has recently addressed the challenges of accessing 
research data for re-analyses. In this scenario statisticians should 
move from their classical role as “gate-keepers” of data to that 
of “data facilitators”.33) Specific techniques are required to ensure 
adequate data manipulation in order to convert the data that was 
collected and entered in the data base into data that is analytically 
usable. Converting row data in standardized formats may be 
challenging. Moreover, familiarity with the required statistical 
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programing language is necessary. Independent statisticians should 
play a major role in guiding the principles of re-analysis based on 
the researchers´  request while, at the same time, guarding against 
misleading conclusions. They should be fully aware that additional 
analyses may yield different results compared with the original 
analyses. Accordingly, they should be prepared to face criticism 
but, at the same time, they should be able to openly challenge 
previous statistical methods.33) 
Statistical guidance may be required for appropriate interpretation 
of results from re-analyses where different methods have been 
utilized. In particular, it is important to keep in mind the inherent 
risk of over-interpretation the results from multiple subgroup 
analyses.34)
Likewise, documents for best practices in data anonymization 
have been developed.35) Statisticians should be familiar with 
this methodology. Risk to patient privacy can be mitigated by 
data reduction techniques. Data holders are responsible for 
generating de-identified datasets to offer protection for patient 
privacy through masking or generalization of main identifiers. In 
addition, legally binding data sharing agreements should include a 
compromise not to attempt to identify patients.35) In particular, it is 
recommended that data use agreements are signed by data holder 
and researchers. Only appropriately qualified “named” researchers 
should be granted access to the data. Finally, high security levels 
should be implemented for data transferring. Resources, costs and 
effort required to make patient-level data available for third party 
research may be considerable and, therefore, adequate funding 
should be organized.35)
Credit to Original Authors
A clear motivation for researches to conduct randomized clinical 
trials is the opportunity to publish different studies in addition 
to the main study with the primary endpoint. These secondary 
analyses may be of major value to unravel new findings from the 
original dataset.36-37) Many have proposed that the time to open the 
process of data sharing should be extended to 2 years, or even to 5 
years in selected complex or large studies. This will allow a precious 
time for the original investigators to further scrutinize and analyze 
in depth their own data. In addition, mechanisms are required 
to ensure that the external analyses are conducted adequately 
and not merely to undermine the original findings. As blinding is 
necessary during trial execution once the study is completed the 
research teams concentrates in publishing the primary findings as 
soon as possible. Following this, usually there is a series of pre-
planned additional analyses. These studies may be organized by 
collaborative teams with investigators from different institutions 
with relatively poor support. Secondary analyses are also very 
important for co-investigators and junior scientists. To respect this 
legitimate interest an extension from the 6 month-period after the 
primary data has been published should be warranted.36-37) 
Credit should be granted to the original researchers that create 
data sets that other investigators find useful.14)15) The academia 
rewards scientists with recognition for making their discoveries 
public. Original investigators may be tempted to consider 
“research parasites” those performing secondary analyses of 
their data. Direct collaboration between primary and secondary 
researches is, therefore, necessary to ensure proper data analysis 
and interpretation. Collaboration with original data gatherers 
is strongly recommended.14)15) The original investigators that 
designed and conducted the trial and obtained sources of founding 
deserve receiving the adequate scientific credit.28) There is a need to 
financially compensate original investigators for their efforts and 
the cost of making trial data available.36)37)
Conclusion
The data transparency revolution is here to stay. This is just another 
step ahead into a culture of open science and it is clear that we are 
at the dawn of a new age.38)39) Challenges and hurdles in adoption 
and implementation of the new ICMJE recommendation will be 
progressively overcome.40) Experience gained by leading journals 
will eventually allow a balanced compromise between the interests 
of the original researchers and that of the scientific community as 
a whole. NSCJ should progressively adapt their policies to increase 
awareness of the importance of data sharing and promote policies 
designed to enhance transparency in biomedical research.
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